Pancreatic cancer vaccine before a tumor appears

A pancreatic cancer vaccine was given here to people who did not have pancreatic cancer. All participants had an inherited predisposition to the disease and an abnormality visible on pancreatic imaging. The unusual goal was to train the immune system against one of cancer's earliest molecular signals before an invasive tumor had appeared.

The study focused on pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. It can evolve from precursor lesions over many years. One of the earliest genetic events is often a mutation in KRAS, a gene whose altered protein can keep growth signals switched on. Mutant KRAS is found in most pancreatic ductal adenocarcinomas and is already present in many of their precursors.

That early event provided the target for the phase 1 study reported in Cancer Discovery.

Six mutations in one vaccine

The experimental vaccine, mKRAS-VAX, is not individually manufactured for each recipient. It contains synthetic long peptides representing six common mutant forms of KRAS: G12D, G12V, G12R, G12C, G12A and G13D. The peptides are administered with the immune-stimulating adjuvant poly-ICLC.

The trial included 20 people with hereditary pancreatic cancer predisposition and a pancreatic abnormality detected on imaging. Participants received four vaccine doses over 13 weeks. The primary purpose was not to establish that the vaccine prevents cancer, but to assess safety and determine whether it could generate a mutant-KRAS-specific immune response.

It did. Eighteen of the 20 participants, or 90%, developed a significant mutant-KRAS-specific T-cell response after vaccination. The median increase in that response was 18.2-fold.

The response was also more than a short-lived burst of immune activity. Both CD4 and CD8 T cells were activated, including memory populations. T-cell receptor sequencing showed that some vaccine-induced clones capable of recognizing mutant KRAS remained detectable for as long as two years.

Why target KRAS before cancer develops?

T cells do not directly inspect mutations in DNA. Cells continuously break down proteins and display small fragments of them on their surface. A KRAS mutation can produce an altered peptide that the immune system recognizes as different. Vaccination is intended to expand T cells capable of recognizing those mutant fragments.

That is the basis of cancer “interception.” Instead of trying to eliminate an established tumor containing billions of cells and surrounded by an immunosuppressive microenvironment, the aim is to target abnormal cells much earlier, while they are still part of a precancerous process.

For now, however, that remains a biological strategy rather than demonstrated cancer prevention.

During a median follow-up of 16.5 months, none of the 20 participants developed pancreatic ductal adenocarcinoma or a high-risk pancreatic lesion requiring surgery. Follow-up imaging also found complete disappearance of small pancreatic cysts in five participants and partial regression in three.

Those observations are intriguing, but they cannot be attributed to the vaccine. There was no unvaccinated control group, and small pancreatic cysts can change over time independently of treatment.

An immune response is not yet cancer prevention

All treatment-related adverse events were grade 1 or 2. The most common included injection-site reactions, fatigue, chills and flu-like symptoms.

The major limitation is the scale and purpose of the trial. Only 20 people were studied, and phase 1 was designed primarily to assess safety and immunogenicity. Pancreatic cancer can develop over many years, making a median follow-up of 16.5 months far too short to determine whether vaccination actually reduces cancer incidence. With no control group, the absence of pancreatic cancer cases also cannot show how many cancers would otherwise have occurred.

The central result is therefore more precise: in people at inherited high risk of pancreatic cancer, an off-the-shelf vaccine targeting several shared KRAS mutations can generate a strong T-cell response before diagnosed cancer is present, and some of those immune clones can persist for years.

The next question is much harder. Researchers must show that these immune responses can actually eliminate relevant precancerous cells and reduce the long-term probability of invasive cancer. If larger and longer trials eventually establish that, vaccination against shared early driver mutations could open a new approach to cancer prevention: not simply treating tumors earlier, but trying to intercept them before they become tumors at all.